Clinical Trials · NCT07684144

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Name: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Maridebart cafraglutide

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Amgen
Enrollment: 950
Start date: Jul 2026
Locations: 37 sites, 3 countries
Primary endpoint: Percent Change in Body Weight from Baseline of the Parent Trial (20210184)

View Maridebart-Cafraglutide compound reference